DART enhances adverse event reporting in aging and serious illness research, suggesting broad applicability for diverse populations.
DART provides a novel solution to AE reporting challenges faced by aging and serious illness researchers. While its design centers on seriously ill older adults, DART can likely be applied to research in any population and intervention type not regulated by the FDA. Future pilot testing will inform implementation.
No takes yet. Share an insight, caveat, or question.
Lubetsky et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: